Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) CEO Sells $229,231.14 in Stock

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) CEO Ted White sold 32,469 shares of the firm’s stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $7.06, for a total value of $229,231.14. Following the completion of the sale, the chief executive officer now directly owns 250,121 shares of the company’s stock, valued at approximately $1,765,854.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Verrica Pharmaceuticals Trading Up 2.0 %

Shares of Verrica Pharmaceuticals stock opened at $7.25 on Friday. The company has a debt-to-equity ratio of 29.58, a current ratio of 3.17 and a quick ratio of 3.04. Verrica Pharmaceuticals Inc. has a 52 week low of $2.86 and a 52 week high of $11.41. The stock has a 50 day moving average price of $8.03 and a two-hundred day moving average price of $6.77.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its earnings results on Monday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.10. The company had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $2.70 million. Verrica Pharmaceuticals had a negative return on equity of 229.26% and a negative net margin of 905.83%. Sell-side analysts forecast that Verrica Pharmaceuticals Inc. will post -1.57 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on VRCA. Needham & Company LLC raised their price objective on Verrica Pharmaceuticals from $8.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. HC Wainwright raised their price objective on Verrica Pharmaceuticals from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of VRCA. Perceptive Advisors LLC boosted its position in shares of Verrica Pharmaceuticals by 40.9% during the fourth quarter. Perceptive Advisors LLC now owns 7,099,182 shares of the company’s stock valued at $51,966,000 after buying an additional 2,060,199 shares during the last quarter. Avoro Capital Advisors LLC boosted its position in shares of Verrica Pharmaceuticals by 35.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 3,999,999 shares of the company’s stock valued at $29,280,000 after buying an additional 1,045,935 shares during the last quarter. BML Capital Management LLC boosted its position in shares of Verrica Pharmaceuticals by 20.0% during the fourth quarter. BML Capital Management LLC now owns 180,000 shares of the company’s stock valued at $1,318,000 after buying an additional 30,000 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Verrica Pharmaceuticals by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company’s stock valued at $7,511,000 after buying an additional 7,609 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Verrica Pharmaceuticals by 8.1% during the second quarter. Bank of New York Mellon Corp now owns 58,680 shares of the company’s stock valued at $428,000 after buying an additional 4,393 shares during the last quarter. Hedge funds and other institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.